At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
In Brief
A Phase 2 clinical trial evaluating Biospecimen Collection, Computed Tomography, and 5 other interventions for Recurrent Adult Lymphoblastic Lymphoma and 8 related conditions. Active but no longer recruiting, targeting 40 participants across 170 sites in 2 countries.
Detailed Summary
This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with vincristine in treating patients with T-cell or B-cell acute lymphoblastic leukemia that has come back (recurrent) or does not respond to treatment (refractory). Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as vincristine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with vincristine may work better in treating patients with acute lymphoblastic leukemia compared to vincristine alone.
Study Details
Timeline
Interventions
Undergo blood sample collection
Undergo CT scan
Undergo lumbar puncture
Undergo PET scan
Given PO
Given IV
Given IV